Aldeyra Therapeutics to Participate in Upcoming Investor Conferences
07 September 2022 - 10:00PM
Business Wire
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a
clinical-stage biotechnology company developing innovative
therapies designed to treat immune-mediated diseases, today
announced that Todd C. Brady, M.D., Ph.D., President and Chief
Executive Officer of Aldeyra, will participate in the following
investor conferences in September:
- Citi’s 17th Annual BioPharma Conference (1x1 meetings
only) Wednesday, September 7, 2022 Boston, Mass.
- H.C. Wainwright 24th Annual Global Investment Conference
Wednesday, September 14, 2022 New York, NY
Dr. Brady’s presentation at the H.C. Wainwright 24th Annual
Global Investment Conference is scheduled to begin at 10:00 a.m. ET
Wednesday, September 14, 2022. To view the live webcast, log in to
the Investors & Media section of the Aldeyra website at
https://ir.aldeyra.com. A replay will be available following the
presentation and will be archived on the website for 90 days.
About Aldeyra
Aldeyra is a clinical-stage biotechnology company developing
innovative therapies designed to treat immune-mediated diseases.
Our approach is to discover pharmaceuticals that modulate
immunological systems, instead of directly inhibiting or activating
single protein targets, with the goal of optimizing multiple
pathways at once while minimizing toxicity. Two of our lead product
candidates, reproxalap and ADX-629, target pre-cytokine,
systems-based mediators of inflammation known as RASP (reactive
aldehyde species). Reproxalap is in late-stage clinical trials in
patients with dry eye disease and allergic conjunctivitis. ADX-629,
an orally administered RASP modulator, is in Phase 2 clinical
testing for the treatment of systemic immune-mediated diseases. Our
pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%),
in development for the prevention of proliferative
vitreoretinopathy and the treatment of retinitis pigmentosa and
primary vitreoretinal lymphoma. For more information, visit
https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and
Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220906006042/en/
Investor & Media Contact: Scott Solomon Sharon
Merrill Associates, Inc. Tel: (857) 383-2409
ALDX@investorrelations.com
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Aldeyra Therapeutics (NASDAQ:ALDX)
Historical Stock Chart
From Mar 2023 to Mar 2024